-
Androgen Deprivation Therapy (ADT): suppression/blockade of testosterone production/action.
-
Aromatase Inhibitor (AI): blocks aromatase (CYP19A1) → ↓ estrogen (anastrozole/letrozole/exemestane).
-
Selective Estrogen Receptor Modulator (SERM): tamoxifen—ER antagonist in breast, partial agonist in bone/endometrium.
-
Selective Estrogen Receptor Degrader (SERD): fulvestrant—binds ER and triggers degradation.
-
CYP17A1: androgen-synthesis enzyme targeted by abiraterone.
-
Gonadotropin-Releasing Hormone (GnRH): hypothalamic hormone controlling LH/FSH (agonists/antagonists suppress gonadal steroids).
-
DiHydroEpiAndrosterone (DHEA): androgen precursor supplement; avoid during endocrine therapy.
-
International Prostate Symptom Score (IPSS): urinary symptom scale, 0–35.
-
Intrauterine Device (IUD), Copper: non-hormonal contraception of choice during endocrine therapy.
-
Osteonecrosis of the Jaw (ONJ): serious antiresorptive complication—avoid implants/extractions on therapy.
-
RECIST v1.1: imaging response criteria.
-
Dual-Energy X-ray Absorptiometry (DEXA): bone mineral density scan.
-
EORTC QLQ-C30, SF-36, FACT-P: validated QoL instruments (oncology general, general health, prostate-specific).
-
ESR1/AR-V7: mutations/variants associated with endocrine resistance.